Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice
Katerina T. Xenaki, Bram Dorresteijn, Joey A. Muns, Kevin Adamzek, Sofia Doulkeridou, Hendrik‐Jan Houthoff, Sabrina Oliveira, Paul M.P. van Bergen en Henegouwen
Abstract
Our results demonstrate that genetic fusion of a nanobody to ABD can significantly extend serum half-life, resulting in prolonged and homogenous tumor accumulation. Most importantly, as supported by the impressive anti-tumor efficacy observed after a single dose administration of 11A4-ABD-AF, our data reveal that monovalent internalizing ABD-fused nanobodies have potential for the development of highly effective NDCs.
Topics & Concepts
In vivoBiodistributionChemistryIn vitroInternalizationConjugateDistribution (mathematics)AlbuminEx vivoPharmacokineticsPharmacologySerum albuminAntibodyMonoclonal antibodyCancer researchMolecular biologyMedicineImmunologyBiochemistryReceptorBiologyMathematical analysisBiotechnologyMathematicsMonoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchGlycosylation and Glycoproteins Research